Skip to main content
OpenTrials
Completed

NCT Number: NCT03261609

Risk of Chronic Diseases in Young Adults Born Preterm: Relationship With Inflammation and Oxidative Stress Biomarkers.

The purpose of the HAPI project is to study the overall health of preterm infants once they reach adulthood. The investigators would like to compare the health of adults born preterm with that of adults born full-term. They would also like to find the early signs, or biomarkers, of chronic diseases such as high blood pressure, diabetes, osteoporosis, and chronic lung diseases.

Such biomarkers would allow for early diagnosis and prevention. Furthermore, the investigators would like to understand why some people born preterm are more likely to develop chronic disease. They believe that inflammation and oxidative stress may play a part. Oxidative stress is present when the body is not able to defend itself against oxygen-derived products that can damage our cells.

To carry out this study, the investigators will examine 6 aspects of the health: (1) heart and circulation, (2) kidneys, (3) lungs, (4) metabolism - sugars and fats in the blood, (5) bones, and (6) eyes.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The participants, from both groups will spend a whole day at St. Justine's hospital. Upon arrival after an overnight fast, vital signs and anthropometric measures are taken. Then blood and urine are obtained as well and a pregnancy test is performed for women. After inserting a intravenous catheter, around 55 mL of blood is taken and sent to the biochemistry department and to our laboratory. A oral glucose tolerance test is also performed with blood sampling over 2hours.

Then a renal and carotid ultrasounds, as well as a osteodensitometry test (bone mineral density and body muscle/fat composition) are done. Ophtalmology exam is realized by ophtalmologist, including visual acuity, contrast and fundus photograph, then the participants are provided with a standardized light lunch.

A thorough cardiac ultrasound, as well as assessment of major arteries (aorta, carotid, brachial) structure and function are performed. Pulmonary function tests are done before a fitness test for VO2 max, and repeated with bronchodilatator after the fitness test.

Prior to leaving, participants are given a ambulatory blood pressure monitor for them to carry for 24 consecutive hours over the following 2 days.

Prior to the study day, participants are sent questionnaires to be filled in advance by themselves and by each of their parent. During the study day, other questionnaires regarding their lifestyles and medical condition are also filled. Overall, information is obtained about:

(1) Socio-economic status: Occupation, education level and income of participant and parents. (2) Family history: Parental health (including maternal pregnancies) and familial (1st and 2nd degree) premature history of cardiovascular diseases (CVD), type-2 diabetes, chronic pulmonary or renal diseases. (3) Personal medical history: Current medication use (including anti-inflammatory medications), medical history, current symptoms, and growth parameters from birth to present (according to medical records and child health care booklet), age at menarche.

(4) Health-related behaviors: (a) regular physical activities (Minnesota and Huet validated questionnaires) (b) Smoking and alcohol consumption. (c) Diet assessed through the validated and self-administered 73-item Food Frequency Questionnaire (FFQ). (d) SF-36 Health Survey.

In addition to the study protocol, the subjects are invited to contribute extra biosamples to our blood (3 ml) and urine (1 ml) biobank.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

EPT :

  • Birth at GA<29 wks
  • Age 18-29 years at the time of assessment (age of peak human physiological function)

Terms:

  • Birth at GA ≥37 wks
  • Born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood
  • Birth date within 2 years of index case
  • Age 18-29 years at the time of assessment
  • Same self-reported race as preterm participant.

Exclusion criteria

Both groups :

  • Currently pregnant due to X-ray related risks
  • Severe neurosensory deficit preventing test completion.
  • In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study

Treatment and study plan

preterm birth

Other

The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)

Primary outcomes

  1. Markers of inflammation

    Time frame: 1 hour

    Blood samples for measurements of biomarkers of inflammation are collected in the morning the day of the visit. Monocyte chemoattractant-1 (pg/mL), Interleukine-6 (pg/mL), tumor necrosis factor-alpha (pg/mL), intercellular adhesion molecule-1 (pg/mL), vascular cell adhesion molecule-1 (pg/mL), high-sensitivity C-reactive protein (pg/mL).

  2. Markers of oxydative stress in the blood

    Time frame: 1 hour

    Blood samples for measurements of biomarkers of oxidative stress are collected in the morning the day of the visit. Blood : Glutathione (GSH and GSSG (nmol/mg of proteins)) and Redox potential using the Nernst equation and the values of GSH and GSSG (mV).

  3. Markers of oxydative stress in the urine

    Time frame: 1 hour

    Urine 8-prostaglandin F2-alpha (pg/mL).

  4. Markers of oxydative stress in the plasma

    Time frame: 1 hour

    Oxidized LDL (U/L)

Secondary outcomes

  1. CVD risk factors and indicators of (sub)clinical disease: blood pressure

    Time frame: 1 hour

    Blood pressure (mmHg)

  2. CVD risk factors and indicators of (sub)clinical disease: Cardiac structure and function by echocardiography- LV hypertrophy #1

    Time frame: 30 min

    Cardiac structure and function by echocardiography. Left ventricle hypertrophy determined by the LV mass (g) indexed to body surface area (BSA in m2) giving a unit of g/m2.

  3. CVD risk factors and indicators of (sub)clinical disease: Cardiac structure and function by echocardiography- LV hypertrophy #2

    Time frame: 30 min

    Cardiac structure and function by echocardiography. Left ventricle hypertrophy determined by the interventricular septum thickness (cm).

  4. CVD risk factors and indicators of (sub)clinical disease: Cardiac structure and function by echocardiography -LV hypertrophy #3

    Time frame: 30 min

    Cardiac structure and function by echocardiography. Left ventricle hypertrophy determined by LV dysfunction (%) or by endocardial fractional shortening (%)

  5. CVD risk factors and indicators of (sub)clinical disease: Arterial structure and function by ultrasound.

    Time frame: 1 hour

    Arterial structure and function (mm) will be measured using a Dopller ultrasound.

  6. CVD risk factors and indicators of (sub)clinical disease: Adiposity measures #1

    Time frame: 15 min

    Body mass index in kg/m2, calculating using the weight in kg and the height in m

  7. CVD risk factors and indicators of (sub)clinical disease: Adiposity measures #2

    Time frame: 30 min

    Using lean and fat body (g) m

  8. CVD risk factors and indicators of (sub)clinical disease: glucose homeostasis

    Time frame: 2 hours

    Plasma fasting glucose (mmol/L) and insulin (mmol/L) and different times after a 75 g of glucose load.

  9. CVD risk factors and indicators of (sub)clinical disease: Fasting lipid profile

    Time frame: 1 hour

    Plasma triglycerides (mmol/L), HDL (mmol/L) and LDL (mmol/L).

  10. CVD risk factors and indicators of (sub)clinical disease: kidneys functions #1

    Time frame: 30 min

    Urinary protein excretion (albumin/creatinine ratio, mg/mmol), eGFR cystatin C (cystatin C : mg/L) (mL/min/1.73 m2). The formula use the cystatin C values in mg/mL, the standardized serum cystatin min and max, the age (in years) and the sex (female: 0.932, male : 1).

  11. CVD risk factors and indicators of (sub)clinical disease: kidneys functions #2

    Time frame: 15 min

    Use of the eGFR cystatin C formula (cystatin C : mg/L) (mL/min/1.73 m2). The formula use the cystatin C values in mg/mL, the standardized serum cystatin min and max, the age (in years) and the sex (female: 0.932, male : 1).

  12. CVD risk factors and indicators of (sub)clinical disease: pulmonary functions #1

    Time frame: 30 min

    FEV (%)

  13. CVD risk factors and indicators of (sub)clinical disease: pulmonary functions #2

    Time frame: 30 min

    Airflow obstruction (FEV1/FVC ratio, no units).

  14. CVD risk factors and indicators of (sub)clinical disease: Questionnaires #1

    Time frame: 2 hours

    Determinants of health. Questionnaires about socio-economics status, family history, personal medical history.

  15. CVD risk factors and indicators of (sub)clinical disease: Questionnaires #2

    Time frame: 2 hours

    Determinants of health. Maternal obstetrical and subjects neonatal history.

  16. CVD risk factors and indicators of (sub)clinical disease: Questionnaires #3

    Time frame: 2 hours

    Determinants of health. Health-related behaviors

  17. CVD risk factors and indicators of (sub)clinical disease: Questionnaires #4

    Time frame: 2 hours

    Determinants of health. Food frequency questionnaire

Sponsors and collaborators

Lead sponsor

St. Justine's Hospital

Other

Collaborators

  • Jewish General Hospital
  • McGill University Health Centre/Research Institute of the McGill University Health Centre

Registry information

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Aug 25, 2017
Registry last updated
Nov 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.